University of Montreal Hospital Research Centre
Integrated services for conducting early-phase clinical trials in oncology and neurology
One of the most modern research organizations in North America, the University of Montreal Hospital Research Centre (CRCHUM) boasts early clinical research infrastructures that are highly competitive in Canada.
Areas of expertise
- More than 60 investigators involved in early-phase clinical trials (phases I and II);
- Early-phase trials in oncology and neurology, including for first-in-human drug trials;
- Solid and hematological tumours such as head and neck cancer, melanoma, gynecological tumours, thoracic oncology, digestive oncology, breast cancer, prostate cancer, urologic oncology, lymphomas, etc.
- Innovative oncology treatments: manipulation of the microbiota, immunomodulators, targeted therapies, immunocellular therapy, etc.;
- Innovative neurology treatments: multiple sclerosis, amyotrophic lateral sclerosis, Huntington’s disease, progressive supranuclear palsy, etc.
- 15-person team dedicated to early-phase clinical studies (phases I and II) collaborating with more than 60 investigators;
- Close collaboration with the CRCHUM’s translational research core facilities and laboratories;
- Pharmacokinetic and pharmacodynamic studies;
Correlative studies program providing a centralized biospecimen resource for clinical studies.
- Secure unit dedicated to phase l and ll clinical trials, occupying 680 sq. metres of space;
- 15 beds, including 4 closed-off rooms and 11 cubicles. These spaces are equipped with a multifunction computer station;
- Secured laboratory for biospecimen management, handling and shipping;
- More than 18 state-of-the-art scientific core facilities: animal facility, biobanks, cytometry, cellular imaging, experimental imaging, clinical immunomonitoring, metabolomics, microfluidics, molecular pathology, pharmacokinetics, cellular physiology, radiochemistry and cyclotron, transgenesis and animal modelling and CITADEL (the CHUM Center for the Integration and Analysis of Medical Data).
Investigators specializing in phase I trials
Dr. Rahima Jamal — Medical Director of the Unit for Innovative Therapies and hematologist-oncologist: melanoma, head and neck cancer, phase I and II clinical studies
Dr. Simon Turcotte — Hepatobiliary surgeon: gastrointestinal cancer immunobiology, solid cancer immunotherapy, isolation and expansion of anti-tumour T cells; tumour antigen identification
Josée Leclerc, M.Sc., DESS (advanced graduate diploma)
Senior Manager, clinical research
Phone: 514 890-8000, extension 15468